BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 9378449)

  • 1. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
    Kuhn W; Müller T
    Fortschr Neurol Psychiatr; 1997 Aug; 65(8):361-74. PubMed ID: 9378449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson disease. Directed use of modern therapy].
    Möller JC; Wächter T; Oertel WH
    MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.